Australian TGA gives orphan status to thrombocythaemia drug
This article was originally published in Scrip
Executive Summary
The Australian Therapeutics Goods Administration (TGA) has granted orphan status to Orphan Australia's Thromboreductin (anagrelide hydrochloride), 0.5mg and 1mg capsules. Thromboreductin is indicated for the treatment of essential thrombocythaemia in patients with high or intermediate risk of thrombosis or bleeding. It was approved on April 23rd.